Haemonetics Q3 Earnings: Can Momentum Be Sustained?

All eyes are on Haemonetics as the medical technology firm prepares to release its third-quarter fiscal 2026 results tomorrow. The report, due before U.S. markets open, arrives at a pivotal moment. Following a robust previous quarter and the strategically significant acquisition of Vivasure Medical in January, investors are keen to see if the company's recent operational strength has continued.

Analysts have set their forecasts for the quarterly performance. Consensus estimates point to revenue of approximately $331.1 million. This figure would represent a year-over-year decline of roughly 5%. Regarding profitability, the adjusted earnings per share (EPS) are expected to land between $1.25 and $1.27.

Key items for stakeholders to watch include:
* Organic Plasma Growth: Confirmation of the 14% to 17% target range.
* Free Cash Flow: Annual guidance projects a figure between $170 million and $210 million.
* Strategic Integration: Progress on incorporating Vivasure Medical's assets.

The financial data will be published midday Central European Time on Wednesday, February 5.

Should investors sell immediately? Or is it worth buying Haemonetics?

Building on a Foundation of Strong Q2 Performance

The upcoming numbers follow an impressive second quarter. Haemonetics surpassed analyst expectations at that time, posting an adjusted EPS of $1.27 against a consensus estimate of $1.12. Revenue also exceeded projections, coming in at $327.32 million, despite marking a slight decrease compared to the prior year.

Operational efficiency was a standout feature. The company's adjusted gross margin expanded significantly by 380 basis points to reach 60.5%. This strong performance prompted management to raise its full-year fiscal 2026 outlook, issuing adjusted EPS guidance in the range of $4.80 to $5.00.

Strategic Acquisition Fuels Growth Ambitions

A major development shaping the company's future trajectory is the completion of the Vivasure Medical purchase. This acquisition, finalized in January, is viewed by market observers as a crucial strategic move. Vivasure Medical specializes in advanced polymer-based implant technology.

By bringing this capability in-house, Haemonetics substantially broadens its portfolio within the hospital-based vascular management sector. The integration of new vascular closure system technology is seen as a necessary step to unlock fresh growth catalysts beyond the company's core blood management business.